Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / articles / RNA - Avidity Biosciences Says Lead Program Shows Reversal Of Disease Progression In Neuromuscular Disease | Benzinga

RNA - Avidity Biosciences Says Lead Program Shows Reversal Of Disease Progression In Neuromuscular Disease | Benzinga

Avidity Biosciences Inc.

Monday, Avidity Biosciences Inc (NASDAQ:RNA) revealed new long-term AOC 1001 data from the MARINA open-label extension (MARINA-OLE) trial showing reversal of disease progression in myotonic dystrophy type 1 (DM1) patients across multiple endpoints compared to END-DM1 natural history data. 

These are the same key endpoints used in the global Phase 3 HARBOR trial for DM1. 

Also Read: Avidity Biosciences’ Muscle Disease Candidate Shows Improvement in Multiple Additional Functional Endpoints, Safety.

The primary endpoint in ...

Full story available on Benzinga.com
Stock Information
Company Name: Avidity Biosciences Inc.
Stock Symbol: RNA
Market: NASDAQ
Website: aviditybiosciences.com
Menu
RNA RNA Quote RNA Short RNA News RNA Articles RNA Message Board
Get RNA Alerts

News, Short Squeeze, Breakout and More Instantly...